arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

NEUROCRINE BIOSCIENCES INC

NBIX
$159.81 ▼ -6.22 (-3.75%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
81
Health
Excellent
Bullish
auto_awesome

Analytical Summary

NEUROCRINE BIOSCIENCES INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $15.9B
Dividend Yield —
Revenue Growth 21.4% ↘
Op. Margin 21.6% ↘
ROIC 12.9% ↘
FCF / Share $7.52 ↗
Trailing P/E 33.2x
Price / Book 4.9x
FCF Yield 4.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.86B
↑ +21.4% —
Net Income Profit after all expenses
$478.60M
↑ +40.2% —
Operating Margin Operating profit as % of sales
21.6%
↓ -10.6% 78th
FCF / Share Free cash flow per share
$7.52
↑ +35.6% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
81
Returns ↑
80
Cash Quality ↓
81

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 69 quarters